Page last updated: 2024-10-30

metformin and Kidney Neoplasms

metformin has been researched along with Kidney Neoplasms in 36 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Kidney Neoplasms: Tumors or cancers of the KIDNEY.

Research Excerpts

ExcerptRelevanceReference
"Both bortezomib and metformin have been proposed as potential therapeutics in TSC."5.38Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012)
"To evaluate the effect of metformin combined with intensive-exercise diet therapy on glucose and lipid metabolism and islet function in diabetes patients with localized renal cell carcinoma after laparoscopic resection."3.11A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes. ( An, RH; Jin, YS; Li, JW; Liu, Y; Meng, LL, 2022)
"Metformin has been associated with improved survival outcomes in various malignancies."2.61Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. ( Austin, PC; Finelli, A; Hamilton, RJ; Juurlink, DN; Kulkarni, GS; Nayan, M; Punjani, N; Uleryk, E, 2019)
"Metformin is an antidiabetic drug; recent reports have indicated its anti-cancer effects in various cancers, and it is known to have synergistic effects with other drugs."1.72Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. ( Han, WK; Hong, SH; Hwang, HJ; Lee, KS; Park, SY; Yoon, YE, 2022)
"Clear cell renal cell carcinoma (ccRCC) is the most common and lethal form of urological cancer diagnosed globally."1.51Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines. ( Agouni, A; Frantz, R; Munusamy, S; Pasha, M; Sivaraman, SK, 2019)
"Metformin (Met) is a widely available diabetic drug and shows suppressed effects on renal cell carcinoma (RCC) metabolism and proliferation."1.48Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. ( Chen, Y; Huang, Z; Lan, X; Li, L; Lu, G; Mao, S; Wei, M; Xia, Q; Zhao, M; Zhao, Y, 2018)
"Metformin use has been associated previously with a decreased risk of cancer, but its association with renal cell carcinoma has not yet been investigated in observational studies."1.46Metformin and the risk of renal cell carcinoma: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, CR, 2017)
"Metformin use was not significantly associated with disease-free (hazard ratio [HR], 0."1.46Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. ( Austin, PC; Finelli, A; Hamilton, RJ; Jewett, MA; Juurlink, DN; Kulkarni, GS; Nayan, M, 2017)
"Metformin (MF) acts as a tumour-suppressor in renal cell carcinoma (RCC) by inhibiting the AKT/mTOR pathway via AMPK activation."1.43Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression. ( Kalogirou, C; Kneitz, B; Krebs, M; Kurz, F; Riedmiller, H; Schäfer, D; Schneider, A; Vergho, D, 2016)
"With respect to kidney cancer scarce data are available."1.43Use of metformin and risk of kidney cancer in patients with type 2 diabetes. ( Tseng, CH, 2016)
" Limitations include retrospective design and lack of data on metformin dosage and duration of use."1.43Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. ( Cheng, JJ; Kanesvaran, R; Li, H; Ng, LG; Ng, QS; Tan, HS; Tan, MH; Tan, PH; Toh, CK, 2016)
"Metformin inhibits renal cell carcinoma (RCC) cell proliferation both in vitro and in vivo; however, clinical data regarding the effect of metformin in patients with RCC are lacking."1.42The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. ( Boorjian, SA; Cheville, JC; Leibovich, BC; Lohse, CM; Psutka, SP; Stewart, SB; Thompson, RH; Tollefson, MK, 2015)
"Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6."1.42[Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015)
"Oncocytomas are predominantly benign neoplasms possessing pathogenic mitochondrial mutations and accumulation of respiration-defective mitochondria, characteristics of unknown significance."1.42The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. ( Aviv, H; Chan, CS; Ganesan, S; Hakimi, AA; Hsieh, JJ; Joshi, S; Tolkunov, D; White, E; Yao, M, 2015)
"Metformin was able to induce G0/G1 cell cycle arrest and inhibit RCC growth in vitro and in vivo."1.39Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. ( Bai, X; Hu, W; Jia, C; Li, M; Liu, J; Song, B; Zhang, L, 2013)
"Metformin treatment appeared to attenuate mTORC1 signalling in Tsc1(+/-) kidney tissues but not in renal tumours."1.39Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. ( Gallacher, J; Kalogerou, M; Sampson, JR; Shen, MH; Yang, J, 2013)
"Both bortezomib and metformin have been proposed as potential therapeutics in TSC."1.38Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.78)18.2507
2000's0 (0.00)29.6817
2010's28 (77.78)24.3611
2020's7 (19.44)2.80

Authors

AuthorsStudies
Yao, X1
Liu, H1
Xu, H1
Liu, Y2
Li, J1
Song, M1
Qi, G1
Meng, L1
Meng, LL1
Li, JW1
Jin, YS1
An, RH1
Hong, SH1
Lee, KS1
Hwang, HJ1
Park, SY1
Han, WK1
Yoon, YE1
Santoni, M1
Molina-Cerrillo, J1
Myint, ZW1
Massari, F1
Buchler, T1
Buti, S1
Matrana, MR1
De Giorgi, U1
Rizzo, M1
Zabalza, IO1
Galli, L1
Zucali, PA1
Aurilio, G1
Incorvaia, L1
Bassanelli, M1
Mammone, G1
Salfi, A1
Isella, L1
Mollica, V1
Grande, E1
Porta, C1
Battelli, N1
Li, H3
Zhang, L3
Yang, F2
Zhao, R1
Li, X1
Shi, H1
Sun, Y1
He, M1
Yang, X1
Hamada, M1
Fukunaga, T1
Zhang, X3
Chang, C1
Takahashi, M1
Inoue, T1
Huang, M1
Numakura, K1
Tsuruta, H1
Saito, M1
Maeno, A1
Nakamura, E1
Narita, S1
Tsuchiya, N1
Habuchi, T1
Wei, M1
Mao, S1
Lu, G1
Li, L1
Lan, X1
Huang, Z1
Chen, Y1
Zhao, M1
Zhao, Y1
Xia, Q2
Nayan, M2
Punjani, N1
Juurlink, DN2
Finelli, A2
Austin, PC2
Kulkarni, GS2
Uleryk, E1
Hamilton, RJ2
Liu, M2
Zhang, Z1
Wang, H1
Chen, X1
Jin, C1
Pasha, M1
Sivaraman, SK1
Frantz, R1
Agouni, A1
Munusamy, S1
Rieken, M1
Xylinas, E1
Kluth, L1
Trinh, QD1
Lee, RK1
Fajkovic, H1
Novara, G1
Margulis, V1
Lotan, Y1
Martinez-Salamanca, JI1
Matsumoto, K1
Seitz, C1
Remzi, M1
Karakiewicz, PI1
Scherr, DS1
Briganti, A1
Kautzky-Willer, A1
Bachmann, A1
Shariat, SF1
Psutka, SP1
Boorjian, SA1
Lohse, CM1
Stewart, SB1
Tollefson, MK1
Cheville, JC1
Leibovich, BC1
Thompson, RH1
Łukasiewicz, D1
Chodorowska, M1
Jakubowska, I1
Huang, T1
Geng, J1
Zheng, J1
Kalogirou, C1
Schäfer, D1
Krebs, M1
Kurz, F1
Schneider, A2
Riedmiller, H1
Kneitz, B1
Vergho, D1
Tseng, CH2
Joshi, S2
Tolkunov, D1
Aviv, H1
Hakimi, AA1
Yao, M1
Hsieh, JJ1
Ganesan, S1
Chan, CS1
White, E1
Cheng, JJ1
Tan, HS1
Tan, PH1
Ng, LG1
Ng, QS1
Toh, CK1
Kanesvaran, R1
Tan, MH1
Becker, C1
Jick, SS1
Meier, CR1
Bodmer, M1
de Jong, RG1
Nielen, JT1
Masclee, AA1
Janssen-Heijnen, ML1
de Vries, F1
Sayyid, RK1
Fleshner, NE1
Keizman, D1
Ish-Shalom, M1
Sella, A1
Gottfried, M1
Maimon, N1
Peer, A1
Hammers, H1
Eisenberger, MA1
Sinibaldi, V1
Neiman, V1
Rosenbaum, E1
Sarid, D1
Mermershtain, W1
Rouvinov, K1
Berger, R1
Carducci, MA1
Jewett, MA1
Hamieh, L1
McKay, RR1
Lin, X1
Moreira, RB1
Simantov, R1
Choueiri, TK1
Xie, W1
Wang, L1
Sheng, H1
Qiu, J1
Zhang, D1
Tang, D1
Zhang, K1
Li, Y1
Hu, L1
Yuan, Y1
Mi, Y1
Woodard, J1
Viollet, B1
Hay, N1
Platanias, LC1
Gartenhaus, RB1
Liu, J2
Li, M2
Song, B1
Jia, C1
Bai, X1
Hu, W1
Hu, WL1
Jia, CH1
Li, HY1
Wen, ZH1
Zou, ZP1
Bai, XC1
Luo, SQ1
Auricchio, N1
Malinowska, I1
Shaw, R1
Manning, BD1
Kwiatkowski, DJ1
Yang, J1
Kalogerou, M1
Gallacher, J1
Sampson, JR1
Shen, MH1
Gowardman, JR1
Havill, J1

Reviews

5 reviews available for metformin and Kidney Neoplasms

ArticleYear
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
    BioMed research international, 2021, Volume: 2021

    Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm

2021
Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Analgesics, Opioid; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophag

2023
Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis.
    American journal of clinical oncology, 2019, Volume: 42, Issue:3

    Topics: Humans; Hypoglycemic Agents; Kidney Neoplasms; Metformin; Prognosis; Survival Rate

2019
Potential role for metformin in urologic oncology.
    Investigative and clinical urology, 2016, Volume: 57, Issue:3

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal

2016
The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis.
    International urology and nephrology, 2017, Volume: 49, Issue:6

    Topics: Carcinoma, Renal Cell; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Kidney

2017

Trials

1 trial available for metformin and Kidney Neoplasms

ArticleYear
A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes.
    Disease markers, 2022, Volume: 2022

    Topics: Blood Glucose; Carcinoma, Renal Cell; Cholesterol; Diabetes Mellitus, Type 2; Glucose; Humans; Hypog

2022

Other Studies

30 other studies available for metformin and Kidney Neoplasms

ArticleYear
High-Concentration Metformin Reduces Oxidative Stress Injury and Inhibits the Growth and Migration of Clear Cell Renal Cell Carcinoma.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D; Humans; Kidney

2022
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
    Genes, 2022, 07-06, Volume: 13, Issue:7

    Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Kidney Neoplasms; M

2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
    Targeted oncology, 2022, Volume: 17, Issue:5

    Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito

2022
Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
    Oncogene, 2020, Volume: 39, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Re

2020
Inverse relationship between insulin receptor expression and progression in renal cell carcinoma.
    Oncology reports, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, CD; Carcinoma, Renal Cell; Diet, Carbohydrate Loa

2017
Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
    BMC cancer, 2018, 04-17, Volume: 18, Issue:1

    Topics: Acetylation; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Res

2018
Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2.
    International journal of biological sciences, 2019, Volume: 15, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Huma

2019
Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
    Biomolecules, 2019, 03-22, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Cell Sur

2019
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem

2014
The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma.
    Urologic oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents;

2015
[Obesity as a factor in the development of cancer in type 2 diabetes].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2015, Volume: 38, Issue:225

    Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans

2015
Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpo

2015
Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression.
    Urologia internationalis, 2016, Volume: 96, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Female;

2016
Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 52

    Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inc

2016
The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.
    Cell reports, 2015, Dec-01, Volume: 13, Issue:9

    Topics: Adenoma, Oxyphilic; AMP-Activated Protein Kinases; Autophagy; Carcinoma, Renal Cell; Cathepsins; Cel

2015
Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:2

    Topics: Aged; Carcinoma, Renal Cell; Diabetes Mellitus; Female; Humans; Kidney Neoplasms; Male; Metformin; M

2016
Metformin and the risk of renal cell carcinoma: a case-control analysis.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2017, Volume: 26, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Case-Control Studies; Diabetes Mellitus; Fema

2017
Comments on "Use of metformin and risk of kidney cancer in patients with type 2 diabetes", Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19-25.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 61

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Neoplasms; Metformin; Risk

2016
Response to Letter to the Editor on comments on Use of metformin and risk of kidney cancer in patients with type 2 diabetes Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19-25.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 61

    Topics: Diabetes Mellitus, Type 2; Humans; Kidney Neoplasms; Metformin; Risk

2016
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:5

    Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Disease-Free Surviva

2016
Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Diabetes Mellitus; Disease-Free Survival; Female; Hu

2017
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, P

2017
Metformin Induces Growth Inhibition and Cell Cycle Arrest by Upregulating MicroRNA34a in Renal Cancer Cells.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Jan-03, Volume: 23

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; C

2017
AMPK as a therapeutic target in renal cell carcinoma.
    Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Cell Growth Proces

2010
AMPK signaling: a targetable tumor suppressor pathway?
    Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Humans; Kidney Neo

2010
Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.
    Urologic oncology, 2013, Volume: 31, Issue:2

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tum

2013
[Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:9

    Topics: Apoptosis; Carcinoma, Renal Cell; Caspase 9; Cell Line, Tumor; Cell Proliferation; Humans; Kidney Ne

2011
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Imm

2012
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6

    Topics: Animals; Azacitidine; Blotting, Western; Catecholamine Plasma Membrane Transport Proteins; Decitabin

2013
Fatal metformin induced lactic acidosis: case report.
    The New Zealand medical journal, 1995, Jun-14, Volume: 108, Issue:1001

    Topics: Acidosis, Lactic; Fatal Outcome; Female; Humans; Kidney Neoplasms; Metformin; Middle Aged; Postopera

1995